Please login to the form below

Not currently logged in
Email:
Password:

neutropaenia

This page shows the latest neutropaenia news and features for those working in and with pharma, biotech and healthcare.

Neulasta rival from Teva cleared in EU

Neulasta rival from Teva cleared in EU

Neulasta rival from Teva cleared in EU. Lonquex offers competition to Amgen drug in neutropaenia. ... Lonquex (lipegfilgrastim) has been approved to reduce the duration of neutropaenia (low white blood cell counts) and febrile neutropaenia in patients

Latest news

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Teva's current efforts in the area include tbo-filgrastim - a biosimilar version of Amgen's Neupogen, which is approved for use to hasten recovery from instances of neutropaenia in certain

  • FDA approves Teva’s biosimilar for neutropaenia in cancer patients

    FDA approves Teva’ s biosimilar for neutropaenia in cancer patients. Neupogen biosimilar already marketed in Europe as Tevagrastim. ... from severe neutropaenia in 1.1 days compared with 3.8 days in those receiving a placebo.

  • R&D news in brief

    ìThe drug appears to be well tolerated, with thrombocytopaenia and neutropaenia, being the main side effects that require careful monitoring.î.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics